Evolving Treatment in Non-muscle-Invasive Bladder Cancer

Benjamin M. Eilender, Andrew B. Katims, John L. Pfail, John Sfakianos

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Treatment for NMIBC is evolving and depends on many factors including cancer pathology, risk stratification, and patient’s medical comorbidities, among many other aspects. Historically, NMIBC has been treated with surgical resection and intravesical BCG. More recently, many other forms of intravesical therapy including non-BCG immunotherapy, chemotherapy, gene therapy, viral therapy, and others, have been studied to treat patients with NMIBC. Primary goals of these new bladder preserving therapies include preventing disease recurrence and disease progression while improving overall survival. This chapter begins with a short introduction into the disease process and then shifts focus to the many treatment options for NMIBC. We discuss surgical management, the role for BCG and other immunotherapy, use of chemotherapy and then go into detail about the newest treatment options and their relevant clinical trials.

Original languageEnglish
Title of host publicationUrologic Oncology
Subtitle of host publicationMultidisciplinary Care for Patients
PublisherSpringer International Publishing
Pages313-348
Number of pages36
ISBN (Electronic)9783030898915
ISBN (Print)9783030898908
DOIs
StatePublished - 1 Jan 2022

Keywords

  • BCG
  • Chemotherapy
  • Emerging therapies
  • Immunotherapy
  • Non-muscle-invasive bladder cancer
  • Radical cystectomy
  • Risk stratification
  • Surveillance

Fingerprint

Dive into the research topics of 'Evolving Treatment in Non-muscle-Invasive Bladder Cancer'. Together they form a unique fingerprint.

Cite this